替罗非班在急性心肌梗死急诊PCI中的有效性及安全性  

Behalf of the Efficacy of Tirofiban Drug Efficacy and Safety in Primary PCI in the Treatment of Patients with AMI

作　　者：王彩虹[1] 袁兰所[1] 张慧晶[1] 郑群[1] 

机构地区：[1]衡水市哈励逊国际和平医院心血管内科,衡水053000

出　　处：《中国医药导刊》2013年第7期1209-1210,1212,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:观察血小板糖蛋白IIb/IIIa受体拮抗剂替罗非班在急性心肌梗死(AMI)患者急诊介入治疗(PCI)中的有效性和安全性。方法:将行急诊PCI的患者120例,随机分为替罗非班组64例和对照组56例。比较2组梗死相关血管开通后血流情况,评估TIMI血流分级。同时观察术后与低分子肝素合用活化凝血时间(ACT)有无升高、血小板计数有无下降及出血事件发生率。结果:替罗非班组的患者梗死相关血管TIMI血流3级率为90.7%,高于对照组(P<0.05)。术后活化凝血酶原时间及血小板计数比较差异无统计学意义(P>0.05)。替罗非班不增加患者主要出血风险,但有增加微小出血的风险。结论:替罗非班在AMI急诊PCI中是安全有效的。Objective：To observe drug efficacy and safety of the platelet glycoprotein IIb/IIIa receptor antagonist tirofiban in primary PCI in the treatment of patients with acute myocardial infarction（AMI）.Methods：120 patients undergoing emergency PCI were randomly divided into 2 groups： 64 cases in tirofiban grooup and 56 patients in control group.After the opening of the two groups were compared infarct-related artery blood flow,assess TIMI flow grade.At the same time observed the postoperative combined with lowmolecular-weight heparin activated clotting time（ACT） with or without elevated platelet count whether the decreased incidence of bleeding events.Results： The infarct-related artery TIMI flow grade 3 of patients in tirofiban grooup was 90.7%,higher than that of the control group,the difference was statistically significant（P＆lt;0.05）.Postoperative activation of prothrombin time and platelet count difference was not statistically significant（P＆lt;0.05）.Tirofiban does not increase the risk of major bleeding in patients,but increase the risk of minor bleeding.Conclusion：Tirofiban involved in the emergency treatment of acute myocardial infarction in the process is safe and effective.

关 键 词：替罗非班 急性心肌梗死 急诊PCI 

分 类 号：R542.22[医药卫生—心血管疾病]